"Hecto Innovation Expected to Maintain Growth in Core Business and Consolidated Subsidiaries"

An analysis has suggested that Hecto Innovation's core business and its consolidated subsidiaries will continue to grow.

On August 10, Yuanta Securities stated in a report regarding Hecto Innovation's second-quarter results, "Both the core business and consolidated subsidiaries achieved growth," and added, "If the stablecoin business, which could serve as a growth trigger in the core business, becomes more concrete, we expect the company's share price to follow a different trend than before."

Kwon Myungjun, an analyst at Yuanta Securities, said, "For two consecutive quarters, consolidated revenue has exceeded 100 billion won," and added, "In particular, in the second quarter, the fintech business is likely to achieve quarterly results exceeding 100 billion won again going forward."

Regarding Hecto Healthcare, Analyst Kwon commented, "Since the second quarter of 2025, quarterly revenue has remained above 20 billion won," and interpreted this by saying, "The strong demand for major products such as Desimone seems to be driven by sustainability rather than a temporary trend."

The stablecoin business was also highlighted as a new growth driver. Yuanta Securities explained, "On July 15, the Financial Services Commission announced its plan to institutionalize the issuance and distribution system for stablecoins, which are being utilized as new payment methods in major countries, and to introduce a digital asset act as part of its financial innovation plan." The report continued, "The company is building a stablecoin ecosystem linked with its subsidiaries," and added, "By combining Hectowalletone's wallet technology with the payment infrastructure of its subsidiary Hectofinancial, the company plans to provide stablecoin payment solutions."

Eugene Investment & Securities also published a second-quarter performance review report on the same day, stating, "With Hecto Innovation’s quarterly revenue continuing to grow year-over-year, the figure remained within the 100 billion won range in the second quarter, following the previous quarter," highlighting the company's continued growth.

Park Jongseon, an analyst at Eugene Investment & Securities, commented on Hecto Healthcare, saying, "We expect sales growth as new product lineups for the inner beauty brand ‘Onlytual’ expand, including the skincare line, and as sales channels diversify," and further explained, "Having received individual certification for the functionality of 'helping reduce body fat' from the Ministry of Food and Drug Safety, the company plans to launch relevant new products early next year."

This content was produced with the assistance of AI translation services.